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ABSTRACT
Purpose: Epithelioid hemangioendothelioma (EHE) is an ultra-rare vascular sarcoma with unique clin-
ical features. EHE is characterized by an unpredictable, often protracted, clinical course and highly vari-
able clinical presentation. Due to difficulty recruiting ultra-rare cancer patients, health-related quality
of life (HRQoL) of EHE patients has not yet been studied. The aim of this study was to assess EHE
symptom burden and its impact on HRQoL and psychological distress.
Methods: The study was initiated after EHE patients’ foundations approached our research group to
study HRQoL. Patients were recruited from the international EHE Facebook group from May through
October 2018. Data were collected using the online PROFILES registry. Latent class cluster analysis was
performed to identify groups based on frequently reported symptoms. Differences in HRQoL (EORTC-
QLQ-C30) and psychological distress (Hospital Anxiety and Depression Scale) between symptom-based
clusters were examined.
Results: Among 115 EHE patients from 20 countries, three clusters were identified, with low-, inter-
mediate- and high-symptom burden, respectively. Highly symptomatic patients (33%) had clinically
relevantly lower scores on HRQoL compared to the other two groups (p< 0.001). These patients suf-
fered mostly from pain, insomnia and fatigue. Symptom burden significantly correlated with reduced
daily functioning and high levels of psychological distress. Only for highly symptomatic patients,
HRQoL and symptom levels were worse compared to healthy individuals.
Conclusion: For the first time, we studied HRQoL in a large international cohort of ultra-rare cancer
patients with distinct clinical characteristics, enabled by collaboration with patients and use of social
media. We showed a considerable number of EHE patients were highly symptomatic, with a significant
impact on HRQoL and psychological distress.
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Introduction
About 20–25% of all cancer patients are diagnosed with a
rare cancer, which is defined by an incidence of less than
6–15 per 100.000 persons per year [1]. Rare cancers can pose
many challenges, such as difficulty in training clinicians to
adequately recognize and treat these cancers. Performing
research is complicated by the limited availability of funding,
tumor material and low patient accrual in clinical trials.
Epithelioid hemangioendothelioma (EHE) is an ultra-rare
type of vascular sarcoma, with an estimated incidence of
1/1.000.000 persons per year [2]. EHE patients are not just
confronted with a very rare disease and resulting difficulties
in finding expert clinicians, but also face a notoriously unpre-
dictable and highly variable disease course, ranging from
indolent to quickly progressive disease. Although reported
five-year relative survival of all EHE patients is about 70%
[2,3], a recent study showed that patients with pleural dis-
ease or lymph node metastases had a more aggressive clin-
ical course with only 22–30% 5-year survival [4]. Other
possible risk factors associated with poorer survival include
increasing mitotic activity and larger tumor size [5]. EHE can
occur at all ages but is mostly diagnosed after the second
decade of life [2]. Although EHE lesions can arise virtually
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anywhere in the body, they often present in liver, lungs,
bone, skin and extremities [6]. Approximately 30–50% of
patients are asymptomatic and in the few available studies,
pain is the most prevalent symptom among symptomatic
patients (68–74%) [2,3]. The level of symptom burden per
patient has not yet been studied.
EHE treatment is dependent on the localization, extent
and clinical course of the disease and can consist of watchful
waiting, localized treatment or systemic therapy [7–9]. In
case of uni- or multifocal disease limited to the liver, trans-
plantation surgery with curative intent can be considered
[10]. As for systemic treatment, there is no standard regimen
but patients can be treated with paclitaxel, doxorubicin, tyro-
sine kinase inhibitors, sirolimus or celecoxib [11,12].
The rarity, heterogeneity and unpredictable course of EHE
not only result in uncertainty regarding treatment choices,
but also in paucity of adequate supportive care for patients.
To meet their need for support, EHE patients from across the
world have connected through a closed community on social
media platform Facebook. Within this Facebook group EHE
patients and family members share knowledge and personal
experiences reflecting the impact of EHE on daily life.
To date, the impact of EHE on daily life and health-related
quality of life (HRQoL) has not yet been studied. To investi-
gate this in the underexposed very rare sarcoma population,
a representative of the EHE community approached us to ini-
tiate a study within their Facebook group. As EHE is known
to have a highly variable clinical course with varying inten-
sity of symptoms, we aimed to study HRQoL and psycho-
logical distress in relation to symptom burden. In addition,
we intended to test the feasibility of a unique research
method using a patient Facebook group to perform a global
web-based HRQoL study in an ultra-rare cancer.
Methods
Setting and population
This cross-sectional study was initiated upon request of the
EHE patient community. Based on input from EHE patients,
EHE foundation members, clinician experts and HRQoL
researchers, an HRQoL questionnaire was assembled. EHE
patients (age  18 years) were invited to participate through
posts in the Facebook group by one of the researchers
(MW). In addition, the UK, US and Australian EHE foundations
invited their members by email. Participants had to confirm
they were indeed an EHE patient in the Informed Consent
form and were asked in the questionnaire whether their EHE
diagnosis was histologically confirmed. Only English ques-
tionnaires were used. Ethical approval for the study was
obtained from the local certified Medical Ethics Committee
of the Radboud University Medical Center, Nijmegen, The
Netherlands (File number 2017-3922).
Data collection
Data collection was performed using the web-based Patient
Reported Outcomes Following Initial treatment and Long-
term Evaluation of Survivorship (PROFILES) registry, a data
management system allowing secure data collection of
patient-reported outcomes via online questionnaires [13].
Patients were enrolled between May and October 2018.
Study measures
Sociodemographic and clinical characteristics
Clinical information was self-reported. Comorbidity at the
time of survey was assessed by the Self-administered
Comorbidity Questionnaire, evaluating the prevalence of 14
comorbidities [14].
Health-related quality of life
HRQoL was measured by the European Organization for
Research and Treatment of Cancer (EORTC) Core Quality
of Life Questionnaire (EORTC-QLQ-C30) [15]. This 30-item
HRQoL questionnaire consists of five functional scales (phys-
ical, role, cognitive, emotional and social), a global quality
of life scale (overall health and overall quality of life during
the past week), three symptom scales and single items
assessing symptoms and financial impact of the disease.
After linear transformation, all scales and single-item meas-
ures ranged from 0-100. A higher score on the functional
scales and global QoL means better functioning and
HRQoL, whereas a higher score on the symptom scales
means more complaints. Clinically important differences in
functioning were determined according to the guidelines of
the EORTC Quality of Life Group [16] and divided into three
size classes: large (representing unequivocal clinical rele-
vance), medium (likely to be clinically relevant, but to a
lesser extent), and small (subtle but, nevertheless, clinic-
ally relevant).
EHE-specific symptoms were added to the questionnaire
based on input from posts within the Facebook group, EHE
patients and expert clinicians. These symptoms were
assessed by relevant items from the EORTC Item Library,
which contains validated questions from HRQoL question-
naires [17]. Linear transformation was applied to generate
score ranges from 0-100.
Psychological distress
Since symptoms of cancer may overlap with somatic com-
plaints of depression (e.g. fatigue or weight loss), we used
the Hospital Anxiety and Depression Scale (HADS) to assess
self-reported depressive symptoms such as anhedonia and
loss of interest [18]. The HADS consists of 14 items, 7 items
for depressive symptoms and 7 items for anxiety, assessing
levels of symptoms in the last week. Questions were
answered on a 4-point Likert-scale and the total score for
each scale could range from 0 to 21. Cutoff value for symp-
toms of anxiety and depression was indicated by a score 8
[18–20]. Clinically relevant differences were determined
according to Norman’s rule of thumb ¼ 0.5 standard devi-
ation [21].
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Statistical analysis
Latent class cluster analysis was performed to identify clus-
ters of EHE patients based on symptom burden. Latent
class modeling aims to classify similar objects through a
data-driven approach, with respect to a set of variables,
into mutually exclusive groups [22]. Variables used to define
symptom clusters were dichotomous symptom scores of
ten relevant symptoms according to expert opinion, of
which seven were derived from the QLQ-C30 and recoded
into dichotomous scores (fatigue, nausea, appetite, insom-
nia, pain, constipation, diarrhea), with all positive answers
ranging from ‘a little’ to ‘very much’ recoded into ‘yes’.
Three additional symptoms from the EORTC Item Library
were added (skin-, respiratory- and stomach problems). The
optimal number of clusters was based on goodness-of-fit
statistics. Bivariate residuals were assessed to check if the
local independency assumption was met (values <3) [22].
Cluster analyses were conducted with Latent GOLD version
5.2.0 (Statistical Innovations, Belmont, MA, USA). After clus-
ter identification, differences between clusters were exam-
ined with t-tests or analysis of variance (ANOVA) for
continuous variables and v2-tests for categorical variables,
where appropriate (SPSS Statistics, version 25.0, IBM SPSS,
Chicago, IL, USA).
The same analytical techniques were used to determine
differences in HRQoL between our study population and
healthy controls [23]. Healthy controls were randomly
selected from a sample of 15,306 individuals from the
EORTC Norm Data study [23], containing people from across
11 European Union (EU) countries, Russia, Turkey, Canada
and United States (n 1000/country). Since 27% of our
patients came from other countries, we decided to match
by age and sex only (matching ratio 1:18) to the entire EHE
cohort and per symptom cluster. In addition we analyzed
whether selection of only norm data from the USA, Canada
and Europe (73% of our cohort) changed our findings.
Results
Patient characteristics
A total of 138 patients registered for participation. Twenty-
one (15%) patients did not start the questionnaire and were
excluded. Two patients did not complete the survey for
unknown reasons. Therefore, 115 patients from 20 countries
were available for analysis, with a mean age of 47 (range
17–81) years. The majority of patients was female (77%),
lived in the USA (47%) and had no current treatment (80%)
(Table 1 and Supplementary Table S1). All patients reported
histological confirmation of their EHE diagnosis.
In latent class cluster analysis, the three-cluster model had
the best model fit based on the more liberal goodness-of-fit
statistics AICLL and AIC3LL, whereas the two-cluster model
had the best model fit based on the more conservative BICLL
and CAICLL indexes (Supplementary Table 2). We felt that the
three-cluster model best described the variation of symptom
burden in our population and was therefore more relevant
to our research question. The three clusters consisted of EHE
patients with low symptom burden (cluster 1, n¼ 31, 27%),
intermediate symptom burden (cluster 2, n¼ 46, 40%) and
high-symptom burden (cluster 3, n¼ 38, 33%). Among
patients with low symptom burden, 48% (15/31) reported
none of the 10 symptoms.
Mean age or gender distribution did not differ between
the three clusters (Table 1). Patients in the highly symptom-
atic cluster more often reported not having a partner, having














N (%) p Value
Gender
Women 88 (77) 23 (74) 36 (78) 29 (76) 0.918
Age
Mean (range) 47 ± 15 (17-81) 45 ± 14 (17-69) 48 ± 16 (19-81) 48 ± 15 (22-75) 0.545
Age (diagnosis)
Mean (range) 43 ± 15 (13-77) 38 ± 14 (13-64) 44 ± 16 (15-77) 44 ± 15 (18-72) 0.206
Time since diagnosis
Mean (years, range) 4.5 ± 4.3 (0-21) 6.2 ± 5.1 (0-17) 4.0 ± 4.1 (0-21) 3.8 ± 3.4 (0-12) 0.044
Comorbidities
Mean no. (range) 2.0 ± 1.7 (0-8) 1.4 ± 1.1 (0-4) 1.6 ± 1.2 (0-5) 2.9 ± 2.1 (0-8) 0.000a,b
Partner
Yes 95 (83) 27 (87) 42 (91) 26 (68) 0.017
Level of education 0.571
Low 12 (10) 4 (13) 4 (9) 4 (11)
Middle 38 (33) 9 (29) 13 (28) 16 (42)
High 54 (47) 13 (42) 25 (54) 16 (42)
Other 11 (10) 5 (16) 4 (9) 2 (5)
Sick leave because of EHE
Yes 7 (6) – – 7 (18) 0.000
Current state of disease
No evidence of disease 23 (20) 9 (29) 7 (15) 7 (18) 0.002
Indolent (stable/slowly growing) 70 (61) 20 (65) 31 (67) 19 (50)
Aggressive 8 (7) – – 8 (21)




comorbid conditions, and bone and/or pleura lesions (Table
1 and Supplementary Table 1, p¼ 0.001). They also more fre-
quently reported aggressive disease stage (p¼ 0.001) and
fewer years since diagnosis (p¼ 0.044).
HRQoL differences between clusters
Global QoL was significantly lower in the intermediate (mean
75.9± 17.5 SD) and highly symptomatic cluster (56.1 ± 19.4 SD)
compared to the low symptom burden cluster (91.7 ± 7.8 SD),
with differences of large clinical importance [16] between all
three clusters (Table 2). Patients with a high symptom burden
reported 25–30 points lower scores on physical, role, cognitive
and social functioning scales; which are considered large clin-
ical differences. Physical functioning also showed a large clin-
ical difference between the intermediate and highly
symptomatic cluster. Emotional functioning was significantly
worse in the intermediate and highly symptomatic cluster
compared to the low symptom burden cluster.
HRQoL differences between EHE patients and
normative population
Overall, EHE patients reported similar levels of daily function-
ing compared to healthy controls (n¼ 2185), except for social
functioning which was significantly worse for EHE patients
(Table 2). Global QoL was significantly better for EHE patients
than for the normative population. When comparing the
symptom clusters to their respective normative populations,
patients with low and intermediate symptom burden
reported higher or similar functioning compared to their
respective normative populations (n¼ 558 and n¼ 828)
(Figure 1(A,B)). Highly symptomatic patients, however, had
significantly lower global QoL and functioning than healthy
controls in all domains except for emotional functioning
(Figure 1(C)). In addition, we found that inclusion of only
norm data from the USA, Canada and Europe did not signifi-
cantly change our results.
Symptom burden
Insomnia, fatigue and pain were the most commonly
reported symptoms for all patients (Figure 2 and
Supplementary Table S3). In the highly symptomatic cluster,
mean scores on these symptoms varied from 47 (±28SD) on
pain to 65 (±27SD) on insomnia and were significantly higher
than in their normative population (n¼ 684, Data not











N¼ 38 p Value
Global health/QoL 74 ± 21 65 ± 22 0.000 92 ± 8 76 ± 18 56 ± 19 0.000a†,b†, c†
Functioning scales
Physical functioning 86 ± 19 84 ± 19 0.414 98 ± 5 92 ± 12 68 ± 21 0.000b†,c†
Role functioning 81 ± 28 84 ± 25 0.155 99 ± 4 84 ± 22 61 ± 33 0.000a#,b†,c

Emotional functioning 75 ± 23 72 ± 25 0.200 91 ± 13 73 ± 23 64 ± 21 0.000a,b
Cognitive functioning 82 ± 20 83 ± 22 0.590 94 ± 10 85 ± 18 69 ± 22 0.000b†,c#
Social functioning 76 ± 30 85 ± 25 0.000 97 ± 12 85 ± 18 47 ± 30 0.000a
,b†,c†
Summary score 82 ± 16 82 ± 17 0.892 98 ± 3 86 ± 7 64 ± 14 0.000a,b,c




All scores indicate mean ± standard deviation.




































































































Figure 1. EORTC-QLQ-C30 functioning scores per symptom cluster and norma-
tive population. Bar charts showing EORTC-QLQ-C30 global QoL and function-
ing scores for (a) the low symptomatic cluster and its normative population, (b)
for the intermediate symptom burden cluster and its normative population and
(c) for the highly symptomatic cluster and its normative population. p< 0.05,p< 0.01, p< 0.001, #normative population for that particular symp-
tom cluster.
978 M. E. WEIDEMA ET AL.
shown). Patients in the intermediate or low symptom burden
cluster reported similar or lower symptoms scores compared
to their respective norm populations. For the entire EHE
cohort, symptom scores were comparable to healthy controls
(Supplementary Table S3).
Psychological distress
Higher levels of both anxiety and depression where observed
when symptom burden was higher (Table 3). All of the differ-
ences in mean HADS scores between clusters were clinically
relevant [21]. When applying cutoff values for anxiety and
depression, about one-third of highly symptomatic patients
were depressed, and 50% experienced anxiety.
Discussion
In this study, we demonstrated feasibility of an international
HRQoL study in patients living with an extremely rare cancer.
Only limited data is available on HRQoL of rare cancer
patients, whereas the impact of more common cancers has
been studied much more extensively. We cooperated with
EHE patients and used a Facebook group for patient recruit-
ment, yielding rapid inclusion of a large number of patients
from 20 different countries worldwide. The PROFILES infra-
structure was essential for secure data collection and feasibil-
ity of this global web-based study [13]. By conventional
research methods, performing a HRQoL study of this scale
with these patients would have been too expensive and
logistically extremely difficult.
We showed that EHE symptom burden varied strongly
between patients, correlating with clinically large differences
in HRQoL functioning scales, anxiety and depression.
Although EHE is often reported to be heterogeneous [7,24],
the present study is the first to demonstrate this diversity by
identification of three symptom clusters. Previous data are
limited to prevalence of symptoms rather than examining




















Figure 2. EORTC-QLQ-C30 symptom scores. Spider plot showing EORTC-QLQ-C30 symptom scores of the low, intermediate and highly symptomatic cluster on a 0-
100 scale, with higher scores indicating more complaints.









N¼ 38 p Value
HADS
Depression score 5.0 ± 3.6 2.6 ± 2.3 4.7 ± 3.3 7.3 ± 3.3 0.000a†,b†,c†
Anxiety score 5.6 ± 3.9 3.0 ± 2.4 5.6 ± 3.8 7.6 ± 3.3 0.000a†,b†,c†




All scores indicate mean ± standard deviation. †Clinically relevant difference according to Norman’s rule of thumb [21].
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present study, 87% of patients reported one or more symp-
toms, compared to 45-72% symptomatic EHE patients in pre-
vious studies [2,3,25].
EHE symptom burden was negatively correlated to HRQoL,
with significant differences in global QoL and all functioning
scales. The association between symptom level and HRQoL is
well-known and has for instance been demonstrated in a large
cohort of cancer survivors, showing lower functioning in patients
with more severe symptoms [26]. The very low levels of HRQoL
scores reported by highly symptomatic EHE patients were remark-
able. They reported comparable levels of physical and role func-
tioning to cancer patients in the last 9-12months of life, whereas
emotional and cognitive functioning were strikingly similar to can-
cer patients in the last 3months of life [27]. Social functioning was
even worse compared to cancer patients in the last 3months of
life [27], although we cannot extract from our data whether
patients in our cohort were in their final months of life.
Pain, fatigue and insomnia were the most prevalent symp-
toms in our cohort, with very high mean symptom scores in
the highly symptomatic cluster. Scores on pain and insomnia
were even higher among highly symptomatic EHE patients
compared to cancer patients in their last 3months of life
[27]. It is uncertain whether the high pain scores in our
cohort are due to inadequate recognition in daily clinical
practice or merely a reflection of the challenge to relieve
EHE-related pain. Whereas patients scored high on fatigue in
the present study, this is not in line with the previously (self)-
reported prevalence of only 3–9% in EHE patients [2,3].
Levels of depression and anxiety were significantly higher
in patients with higher symptom burden. The prevalence of
depression using a cutoff value of 8 points was 19% for the
entire group, similar to the previously reported 18% in cancer
patients in general [28]. In highly EHE symptomatic patients,
34% were depressed. The co-occurrence of depression and
physical symptoms such as pain and fatigue we found in our
study, has been recognized before as a common symptom
cluster in cancer patients [29,30]. Identification of symptom-
based clusters can improve understanding of symptoms and
how they correlate to each other. For future studies in EHE
patients, it would therefore be of interest to examine whether
certain symptoms co-occur and if an intervention targeting
one symptom could alleviate related symptom(s) as well.
Surprisingly, our total cohort of EHE patients had similar
QoL, daily functioning and symptom levels compared to
matched healthy controls. However, specific comparison of
the symptom clusters with their respective normative popu-
lations revealed that only patients with high-symptom bur-
den had significantly lower global QoL and functioning, and
higher symptom scores than healthy controls. These results
emphasize the difference in overall QoL between patients
with low/intermediate symptom burden and those who are
highly symptomatic, and illustrate the large heterogeneity
between EHE patients.
Clinical implications
EHE patients in the highly symptomatic cluster more often
had bone and/or pleural lesions. Highly symptomatic
patients reported both high physical symptom burden and
high levels of psychological distress. The co-occurrence of
physical and psychological symptoms is a well-known phe-
nomenon in cancer patients [31], and their interaction is
illustrated by the finding that treatment of physical symp-
toms can result in improved mood and vice versa [32,33].
Treatment of EHE-related pain can be challenging and there-
fore requires attention and early involvement of pain special-
ists. Use of analgesics could be complemented with
psychosocial interventions, which can be effective in reduc-
ing cancer-related pain [34]. To relieve fatigue in cancer
patients in general, interventions specifically addressing
fatigue were reported to be most promising [35]. However,
in case of co-occurrence of pain and fatigue, adequate pain
control may already improve quality of sleep and reduce
fatigue. Pharmacological or psychological interventions with
regard to depression in cancer patients were reported to be
effective only on the short term (up to 12weeks), however,
the use of a collaborative care approach appeared effective
also on the long term [36].
Strengths and limitations
A unique strength of the current patient-initiated study is
that we were able to include a large number of ultra-rare
cancer patients from 20 different countries by using a social
media platform. The use of EORTC-QLQ-C30 to determine
HRQoL made it possible to compare our results with norma-
tive data from healthy individuals and other cancer popula-
tions. However, due to the study design, all clinical
characteristics were self-reported and could therefore not be
checked for accuracy.
Identification of symptom clusters allowed us to assess
relationships with symptom burden rather than individual
symptoms. Although our design was cross-sectional and
therefore limits causal associations, this is the first study that
provides evidence on HRQoL of EHE patients. Our cohort
may be relatively highly educated, related to internet use
and a potential language barrier for patients from non-
English-speaking countries. We possibly missed patients with
aggressive disease due to quick deterioration. Although we
were able to study a relatively large cohort of EHE patients,
patient numbers were insufficient to perform multivari-
able analyses.
Future perspectives
Overall, our findings support the need to acknowledge
highly symptomatic patients in the clinic and to provide
appropriate supportive care for those patients. Further
research into the cause of the severity of EHE-related pain
could help to better intervene and treat the pain. Because of
the often prolonged clinical course of EHE, performing longi-
tudinal HRQoL research could provide valuable information
about the clinical course over time, its relationship with
HRQoL and therefore appropriate timing of supportive care
interventions. Collection of additional clinical parameters in a
future cohort study would enable for instance assessment of
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clinical risk scores and the correlation between clinical risk
factors and HRQoL. For such a cohort study international col-
laboration would be necessary to establish a relatively large
cohort of EHE patients. Furthermore, additional research
can provide increased awareness among health care profes-
sionals, and assistance in information provision and deci-
sion-making.
Conclusion
In conclusion, we proved international HRQoL research in an
ultra-care cancer feasible, facilitated by cooperation with
patients and online secure data collection. With this study,
we demonstrated that EHE patients can be divided into three
symptom-based clusters, and that physical symptom burden
was strongly associated with HRQoL and psychological dis-
tress. Acknowledgment of the existence of a group with
highly symptomatic patients warrants further research in the
optimal treatment of EHE-related pain.
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